Drug Profile


Latest Information Update: 17 Oct 2016

Price : $50

At a glance

  • Originator Merck Serono
  • Developer Childrens National Health System; EspeRare Foundation; Merck Serono; University of Geneva
  • Class Benzamides; Heart failure therapies; Small molecules; Sulfones
  • Mechanism of Action Sodium hydrogen antiporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Duchenne muscular dystrophy
  • Discontinued Heart failure

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Duchenne muscular dystrophy in Switzerland (PO, Capsule)
  • 01 Nov 2015 Phase-I clinical trials in Duchenne muscular dystrophy (In adolescents, In children) in Spain (PO) (EudraCT2015-002530-50)
  • 04 May 2015 Rimeporide receives Orphan Drug status for Duchenne muscular dystrophy in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top